NOVARTIS AG (NVS)

NYSE Pharmaceutical Pharmaceutical Preparations SIC: 2834
A+
Pipeline Grade

Drug Pipeline (104 Assets)

DrugPhaseIndications
ATRASENTAN HYDROCHLORIDE
VANRAFIA
APPROVED
OCTREOTIDE ACETATE
SANDOSTATIN
APPROVED
LAPATINIB DITOSYLATE
TYKERB
APPROVED
BETAXOLOL HYDROCHLORIDE
BETOPTIC S
APPROVED
OXCARBAZEPINE
TRILEPTAL
APPROVED
OFATUMUMAB
ARZERRA
APPROVED
PAZOPANIB HYDROCHLORIDE
VOTRIENT
APPROVED
FINGOLIMOD HYDROCHLORIDE
GILENYA
APPROVED
HYDROCHLOROTHIAZIDE, VALSARTAN
DIOVAN HCT
APPROVED
IPTACOPAN HYDROCHLORIDE
FABHALTA
APPROVED
INCLISIRAN SODIUM
LEQVIO
APPROVED
TRICLABENDAZOLE
EGATEN
APPROVED
ALPELISIB
VIJOICE
APPROVED
RIBOCICLIB SUCCINATE
KISQALI
APPROVED
TRAMETINIB DIMETHYL SULFOXIDE
MEKINIST
APPROVED
ASCIMINIB HYDROCHLORIDE
SCEMBLIX
APPROVED
TRAMETINIB
MEKINIST
APPROVED
SACUBITRIL, VALSARTAN
ENTRESTO SPRINKLE
APPROVED
BACLOFEN
LIORESAL
APPROVED
ELTROMBOPAG OLAMINE
PROMACTA KIT
APPROVED
DABRAFENIB MESYLATE
TAFINLAR
APPROVED
REMIBRUTINIB
RHAPSIDO
APPROVED
ARTEMETHER, LUMEFANTRINE
COARTEM
APPROVED
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
PLUVICTO
APPROVED
SIPONIMOD
MAYZENT
APPROVED
AMLODIPINE BESYLATE, VALSARTAN
EXFORGE
APPROVED
LETROZOLE, RIBOCICLIB SUCCINATE
KISQALI FEMARA CO-PACK (COPACKAGED)
APPROVED
BASILIXIMAB
SIMULECT
APPROVED
MYCOPHENOLATE SODIUM
MYFORTIC
APPROVED
AMLODIPINE BESYLATE, HYDROCHLOROTHIAZIDE, VALSARTAN
EXFORGE HCT
APPROVED
OXPRENOLOL HYDROCHLORIDE
TRASICOR
NDA Acute Disseminated Encephalomyelitis, Acute Myeloid Leukemia, Adenocarcinoma, Advanced Breast Cancer, Age Related Macular Degeneration, Age Related Macular Degeneration (AMD), Anti-AMPAR-1/2 Associated Autoimmune Encephalitis, Anti-CASPR-2 Associated Autoimmune Encephalitis, Anti-GABAR-1/2 Associated Autoimmune Encephalitis, Anti-GAD65 Associated Autoimmune Encephalitis, Anti-Lgi-1 Associated Autoimmune Encephalitis, Anti-NMDAR Encephalitis, Asthma, Breast Cancer, Breast Cancer Recurrent, Cancer, Carcinoma, Carcinoma, Renal Cell, Chronic Idiopathic Urticaria, Chronic Myeloid Leukemia, Chronic Spontaneous Urticaria, Chronic Urticaria, Clear-cell Metastatic Renal Cell Carcinoma, CNS Lupus, CNS Sarcoidosis, CNS Vasculitis, COVID-19, Ewing's Sarcoma, Failure of Exactly One Prior VEGF-targeted Therapy, Fallopian Tube Neoplasms, Hashimoto Encephalitis, HER 2 Negative Breast Cancer, Her2-negative Locally Advanced Breast Cancer, Her2-negative Metastatic Breast Cancer, HER2/Neu-negative Carcinoma of Breast, High-grade
DICLOFENAC SODIUM
VOLTAREN
NDA
FLUVASTATIN SODIUM
LESCOL
NDA
HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE
APRESAZIDE
NDA
PHENYLBUTAZONE
BUTAZOLIDIN
NDA
ACETYLDIGITOXIN
ACYLANID
NDA
MESORIDAZINE BESYLATE
SERENTIL
NDA
CHLORPHENIRAMINE MALEATE, PHENYLPROPANOLAMINE HYDROCHLORIDE
TRIAMINIC-12
NDA
TERBINAFINE HYDROCHLORIDE
LAMISIL
NDA
TOLAZOLINE HYDROCHLORIDE
PRISCOLINE
NDA
CALCITONIN HUMAN
CIBACALCIN
NDA
CHLORTHALIDONE, METOPROLOL TARTRATE
LOPRESSIDONE
NDA
THIETHYLPERAZINE MALEATE
TORECAN
NDA
OXYPHENBUTAZONE
TANDEARIL
NDA
THIETHYLPERAZINE MALATE
TORECAN
NDA
RIVASTIGMINE TARTRATE
EXELON
NDA
PREDNISOLONE SODIUM PHOSPHATE, SULFACETAMIDE SODIUM
VASOCIDIN
NDA
HYDRALAZINE HYDROCHLORIDE, RESERPINE
SERPASIL-APRESOLINE
NDA
MAZINDOL
SANOREX
NDA
TRIPELENNAMINE HYDROCHLORIDE
PBZ
NDA
FLUMETHASONE PIVALATE
LOCORTEN
NDA
GLYCOPYRROLATE, INDACATEROL MALEATE
UTIBRON NEOHALER
NDA
SULFINPYRAZONE
ANTURANE
NDA
THIORIDAZINE
MELLARIL-S
NDA
DEXAMETHASONE, NEOMYCIN SULFATE, POLYMYXIN B SULFATE
DEXACIDIN
NDA
HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, RESERPINE
SER-AP-ES
NDA
CLOFAZIMINE
LAMPRENE
NDA
ACETAMINOPHEN, CLEMASTINE FUMARATE, PSEUDOEPHEDRINE HYDROCHLORIDE
TAVIST ALLERGY/SINUS/HEADACHE
NDA
HYDROCHLOROTHIAZIDE, PINDOLOL
VISKAZIDE
NDA
CAFFEINE, ERGOTAMINE TARTRATE
CAFERGOT
NDA
ALISKIREN HEMIFUMARATE, AMLODIPINE BESYLATE
TEKAMLO
NDA
ALISKIREN HEMIFUMARATE, AMLODIPINE BESYLATE, HYDROCHLOROTHIAZIDE
AMTURNIDE
NDA
ALUMINUM HYDROXIDE, MAGNESIUM TRISILICATE
FOAMICON
NDA
THEOPHYLLINE SODIUM GLYCINATE
ASBRON
NDA
TELBIVUDINE
TYZEKA
NDA
TRAVOPROST
IZBA
NDA
PHENTOLAMINE MESYLATE
REGITINE
NDA
METOPROLOL FUMARATE
LOPRESSOR
NDA
METHIXENE HYDROCHLORIDE
TREST
NDA
FLUORESCEIN SODIUM
FUNDUSCEIN-25
NDA
DESOXYCORTICOSTERONE ACETATE
PERCORTEN
NDA
CLEMASTINE FUMARATE
TAVIST
NDA
ALISKIREN HEMIFUMARATE, VALSARTAN
VALTURNA
NDA
TRIPELENNAMINE CITRATE
PBZ
NDA
ACETYLCHOLINE CHLORIDE
MIOCHOL
NDA
METOPROLOL TARTRATE
LOPRESSOR
NDA
MEPHENYTOIN
MESANTOIN
NDA
FAMCICLOVIR
FAMVIR
NDA
MAPROTILINE HYDROCHLORIDE
LUDIOMIL
NDA
CERITINIB
ZYKADIA
NDA
CARBACHOL
CARBASTAT
NDA
NAPHAZOLINE HYDROCHLORIDE
VASOCON
NDA
OXYPHENONIUM BROMIDE
ANTRENYL
NDA
DIHYDROERGOTAMINE MESYLATE, HEPARIN SODIUM, LIDOCAINE HYDROCHLORIDE
EMBOLEX
NDA
GUANETHIDINE MONOSULFATE, HYDROCHLOROTHIAZIDE
ESIMIL
NDA
NATEGLINIDE
STARLIX
NDA
LEVOCABASTINE HYDROCHLORIDE
LIVOSTIN
NDA
PREDNISOLONE ACETATE, SULFACETAMIDE SODIUM
VASOCIDIN
NDA
ALSEROXYLON
RAUTENSIN
NDA
GUANETHIDINE MONOSULFATE
ISMELIN
NDA
INDACATEROL MALEATE
ARCAPTA NEOHALER
NDA
FOMIVIRSEN SODIUM
VITRAVENE PRESERVATIVE FREE
NDA
METHYSERGIDE MALEATE
SANSERT
NDA
THIORIDAZINE HYDROCHLORIDE
MELLARIL
NDA
HYDROCHLOROTHIAZIDE, TRIAMTERENE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
NDA
EMEDASTINE DIFUMARATE
EMADINE
NDA
AMINOGLUTETHIMIDE
CYTADREN
NDA
PINDOLOL
VISKEN
NDA
DESOXYCORTICOSTERONE PIVALATE
PERCORTEN
NDA
DESLANOSIDE
CEDILANID-D
NDA
DIBUCAINE HYDROCHLORIDE
HEAVY SOLUTION NUPERCAINE
NDA
ANTAZOLINE PHOSPHATE, NAPHAZOLINE HYDROCHLORIDE
VASOCON-A
NDA
LYPRESSIN
DIAPID
NDA
LODOXAMIDE TROMETHAMINE
ALOMIDE
NDA

Upcoming Catalysts

DateEventDrug
2027-07-01 Phase3 Readout

Active Clinical Trials (7)

NCT #TitlePhaseStatusEnrollment
NCT05918666 National Register of Actionable Mutations OTHER Active Not Recruiting 2,098
NCT05009160 DreaMS - Validation Study 1 OTHER Active Not Recruiting 300
NCT03349801 Development of Novel Clinical Endpoints in Intermediate AMD OTHER Active Not Recruiting 718
NCT02622581 Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients OTHER Recruiting 12,400
NCT05017142 Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) OTHER Recruiting 500
NCT04671693 A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Sur... OTHER Active Not Recruiting 500
NCT04111978 MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) PHASE3 Recruiting 540

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis